Esmo 2021 – Astra finally sees a Wee1 signal
It might be too late for adavosertib, but others could benefit if a niche has finally been found for Wee1 inhibitors.
The reckoning begins for biotech-focused Spacs
The clock is ticking for the flood of blank-cheque companies that raised money last year, and competition is only getting hotter.